LITE
Lumentum Holdings Inc.
LITE's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has a slight edge over LITE overall, supported by lower modeled downside and stronger valuation.
LITE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Healthy | |
| Healthy |
LITE's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LITE PE Valuation
LITE has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LITE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LITE, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LITE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.10 | — |
| Q3 2026 | -$89.47 | -5589% |
| Q2 2026 | -$92.96 | -25224% |
| Q1 2026 | $5.54 | +$12.02 |
| Q4 2025 | $3.40 | +$11.12 |
| Q3 2025 | $1.63 | +$9.94 |
| Q2 2025 | $0.37 | +$8.49 |
| Q1 2025 | -$6.48 | -$1.22 |
| Q4 2024 | -$7.72 | -$3.77 |
LITE has swung to a loss: it lost $89.47 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LITE on earnings quality, reporting a profit while its opponent remains loss making.
LITE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +137% |
| Q2 2026 | $1B | +109% |
| Q1 2026 | $808.4M | +90% |
| Q4 2025 | $665.5M | +65% |
| Q3 2025 | $533.8M | +58% |
| Q2 2025 | $480.7M | +56% |
| Q1 2025 | $425.2M | +16% |
| Q4 2024 | $402.2M | +9.7% |
LITE has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +27 points |
| Q2 2026 | 28% | +30 points |
| Q1 2026 | 22% | +31 points |
| Q4 2025 | 9.7% | +23 points |
| Q3 2025 | 1.3% | +26 points |
| Q2 2025 | -1.8% | +42 points |
| Q1 2025 | -8.9% | +22 points |
| Q4 2024 | -13% | +16 points |
LITE's operating margin was 29% last quarter, up 27 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LITE on profitability, with a higher operating margin.
LITE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | +$56.2M |
| Q2 2026 | $196.2M | +1843% |
| Q1 2026 | $79.1M | +$143.5M |
| Q4 2025 | $43.1M | +$59M |
| Q3 2025 | -$18.3M | +$16.2M |
| Q2 2025 | $10.1M | -7.3% |
| Q1 2025 | -$64.4M | -$37.8M |
| Q4 2024 | -$15.9M | +$16.6M |
LITE's free cash flow has turned positive after three years mostly in the red: $356M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
LITE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.3x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 7.9x | High |
| Q4 2025 | 21.6x | High |
| Q3 2025 | 22.7x | High |
| Q2 2025 | 27.9x | High |
| Q3 2023 | -34.7x | Net Cash |
| Q2 2023 | -7.2x | Net Cash |
LITE's net debt is about 1.3 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over LITE on leverage, with a lower net debt burden relative to earnings.
LITE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 22.8 | Neutral |
LITE's weekly RSI is 42 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LITE PE vs Technology Sector
| Metric | LITE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
LITE has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LITE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $839.3 | 26% below |
| 20 week MA | $838.6 | 26% below |
| 50 week MA | $732.7 | 15% below |
| 100 week MA | $422.7 | 48% above |
| 200 week MA | $237.9 | 163% above |
LITE has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 163% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LITE on trend strength, trading above more of its moving averages.
LITE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $79.0 | $98.3 | +24% |
| 2021 | $98.3 | $104.5 | +6.3% |
| 2022 | $104.5 | $50.6 | -52% |
| 2023 | $50.6 | $52.4 | +3.7% |
| 2024 | $52.4 | $84.4 | +61% |
| 2025 | $84.4 | $390.8 | +363% |
| 2026 YTD | $390.8 | $624.7 | +60% |
LITE has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.